|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1994-1-7
|
|
pubmed:abstractText |
The hypothesis that the results of second line hormonotherapy for breast cancer may be ameliorated with continuation of the first line has been explored in a randomized trial. Patients progressing under tamoxifen were randomly allocated to aminoglutethimide and hydrocortisone acetate with or without tamoxifen continuation. No difference has been observed between the two arms in terms of response rate and progression-free overall survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0277-3732
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
522-5
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8256770-Aged,
pubmed-meshheading:8256770-Aminoglutethimide,
pubmed-meshheading:8256770-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8256770-Breast Neoplasms,
pubmed-meshheading:8256770-Female,
pubmed-meshheading:8256770-Humans,
pubmed-meshheading:8256770-Hydrocortisone,
pubmed-meshheading:8256770-Middle Aged,
pubmed-meshheading:8256770-Neoplasm Metastasis,
pubmed-meshheading:8256770-Neoplasms, Hormone-Dependent,
pubmed-meshheading:8256770-Survival Analysis,
pubmed-meshheading:8256770-Tamoxifen
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
|
|
pubmed:affiliation |
National Institute for Cancer Research, Genova, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
